ABEONA THERAPEUTICS INC. Accounts Receivable, Allowance for Credit Loss
ABEONA THERAPEUTICS INC. (ABEO) had Accounts Receivable, Allowance for Credit Loss of $0 as of 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Balance Sheet › Assets › Accounts Receivable, after Allowance for Credit Loss
us-gaap:AllowanceForDoubtfulAccountsReceivable · last filed 2025-11-12
- 2025-09-30: Accounts Receivable, Allowance for Credit Loss $0.00.
- 2025-06-30: Accounts Receivable, Allowance for Credit Loss $0.00.
- 2016-12-31: Accounts Receivable, Allowance for Credit Loss $0.00.
- 2015-12-31: Accounts Receivable, Allowance for Credit Loss $0.00.
| Period end | Accounts Receivable, Allowance for Credit Loss |
|---|---|
| 2025-09-30 | $0.00 10-Q · filed 2025-11-12 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-14 |
| 2016-12-31 | $0.00 10-K · filed 2017-03-30 |
| 2015-12-31 | $0.00 10-K · filed 2017-03-30 |
| 2014-12-31 | $0.00 10-K · filed 2016-03-30 |
| 2013-12-31 | $0.00 10-K · filed 2015-03-31 |
| 2012-12-31 | $0.00 10-K · filed 2014-03-26 |
| 2011-12-31 | $0.00 10-K · filed 2013-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |